T-HDCs are the Next-Generation ADC Targeted Therapeutics
Dantari has developed a highly innovative and differentiated Targeted High-capacity Drug Conjugate (T-HDC) platform to overcome limitations of first-generation platforms such as traditional antibody-drug conjugates (ADCs) and lipid nanoparticles (LNPs). T-HDCs are designed to provide superior therapeutic profiles with a high drug-to-antibody ratio (DAR~60) for greater efficacy including bystander effect and treating heterogeneous disease.
Based on our proprietary technology, our T-HDC platform is comprised of an optimized high-capacity drug conjugate payload with the added benefit of a targeting binder. The optimization includes tunable release kinetics without the significant ‘burst release’ frequently observed with other delivery platforms. Adding targeting binders enhances efficacy and enables multi-valency or multi-specificity. Furthermore, the surface chemistry of our technology is designed to evade the immune system. Together, these advances combine for greater tumor accumulation and bystander effect for enhanced treatment of patients including those with heterogenous tumors.
Delivery isn’t just local. It’s targeted.
Our unique use of binders drives the treatment into tumor cells and not the rest of the body. This targeting and platform features can reduce the severity of adverse effects and give clinicians greater control and precision for treatment.